Hedge Fund Cheyne Raising Cash for Debt Oversold in Pandemic (Bloomberg) London-based hedge fund Cheyne Capital is planning a new vehicle to buy up debt...
Keep Reading →
May 12 - Hedge Funds, Insider Trading - Comments
Michael Dell’s Money Managers Change How His Wealth Is Invested (The Wall Street Journal) Michael Dell’s money managers are making the most significant...
Keep Reading →
December 6 - Hedge Funds, Insider Trading - Comments
Sound Shore posted 20 year annualized returns of 7.30% and 7.51% for its Sound Shore Fund Investor Class (SSHFX) and Institutional Class (SSHVX), respectively...
Keep Reading →
May 13 - Hedge Funds, News - Comments
CSRA Inc (NYSE:CSRA) (Bloomberg) General Dynamics Corp., the maker of Abrams tanks and nuclear submarines, is making a record bet on reinvigorating its...
Keep Reading →
February 12 - Market Movers, News - Comments
1. U.S. Stock Market: “U.S. equities traded higher on Wednesday as investors cheered the Federal Reserve’s plan for scaling back its massive...
Keep Reading →
May 24 - Commodities, Futures/Forex, Gold, Market Movers, News, Tech - Comments
1. U.S. Stock Market: “The S&P 500 traded higher on Tuesday and nearly erased the losses suffered from the biggest sell-off of the year...
Keep Reading →
May 23 - Commodities, Futures/Forex, Gold, Market Movers, News, Tech - Comments
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has had another misfortune in the UK. The country’s public health watchdog, NICE (the National Institute...
Keep Reading →
February 17 - News, Stock Analysis - Comments
Which are the most successful innovative companies in the world in 2016? Bringing something new to the table is something that seems to be difficult these...
Keep Reading →
October 26 - Hedge Funds, Lists, News - Comments
Crude futures are in the red today as sentiment around the commodity cools off. Meanwhile the Dow, Nasdaq, and S&P 500 are relatively flat as traders...
Keep Reading →
July 28 - Market Movers, News - Comments
U.S stocks have edged higher on Tuesday following a rise in oil prices and Fed Chairwoman Janet Yellen’s speech on Monday, in which she maintained an...
Keep Reading →
June 7 - Market Movers, News - Comments
While several hedge funds have suffered enormous losses this year due to their investments in biotech stocks, the performance of the leading biotech-focused...
Keep Reading →
May 7 - Hedge Fund Analysis, Hedge Funds, News - Comments
Baker Bros. Advisors is a New York City-based fund launched in 2000 by Julian and Felix Baker. The firm focuses on life science and biotechnology companies...
Keep Reading →
February 25 - Hedge Funds, News - Comments
Professional money managers are quick to judge when things start to turn sour for a particular company. Generally, it would do retail investors well ...
Keep Reading →
December 11 - Hedge Funds, News - Comments
Baker Bros. Advisors is one of the most famous healthcare-focused equity hedge funds in the world today. It was founded in 2000 by brothers Julian Baker...
Keep Reading →
December 9 - Hedge Fund Analysis, Hedge Funds, News - Comments
Mariner Investment Group is a New York-based investment advisory firm founded by William Michaelcheck in 1992. Apart from its headquarters in New York...
Keep Reading →
November 13 - Hedge Fund Analysis, Hedge Funds, News - Comments
At Insider Monkey, we track over 700 hedge funds and investment companies, which allows us to understand the market sentiment towards any given stock....
Keep Reading →
August 17 - Hedge Fund Analysis, Hedge Funds, News - Comments
With the rapid pace of M&A happening in the biotechnology sector, Julian Baker and Felix Baker‘s Baker Bros. Advisors is making a habit of hitting...
Keep Reading →
July 10 - Hedge Funds, News - Comments
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Baxter International Inc (NYSE:BAX), and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) are among the top healthcare...
Keep Reading →
June 30 - Hedge Funds, News - Comments
Orphan drugs, those treating rare conditions for small segments of the population, do not normally get much attention compared with the likes of a $12...
Keep Reading →
October 11 - Hedge Funds, News - Comments
Biotechnology stocks often trade with excessive valuations, until one day, large losses occur. The best way to protect yourself is to be logical when...
Keep Reading →
September 16 - News - Comments
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) has priced its Gattex drug for short bowel syndrome, or SBS, at $295,000, expecting to make peak sales of $350...
Keep Reading →
September 11 - News - Comments
A company with a modus operandi of tackling rare and very rare diseases might not necessarily jump out as a great investment, but this company has...
Keep Reading →
September 9 - News - Comments
Is Regeneron Pharmaceuticals Inc (NASDAQ:REGN) a good investment? If you were to ask many investors, hedge funds are viewed as delayed, outdated investment...
Keep Reading →
August 29 - News - Comments
Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) a buy? In the 21st century investor’s toolkit, there are tons of metrics market participants can...
Keep Reading →
August 26 - News - Comments
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) investors are standing pat. In the 21st century investor’s toolkit, there are dozens of indicators investors...
Keep Reading →
August 26 - News - Comments
Who’s buying Amgen, Inc. (NASDAQ:AMGN)? To the average investor, there are tons of metrics shareholders can use to analyze stocks. Some of the...
Keep Reading →
August 25 - News - Comments
Biogen Idec Inc. (NASDAQ:BIIB) investors: listen up. To many market players, hedge funds are assumed to be overrated, old investment vehicles of a forgotten...
Keep Reading →
August 23 - News - Comments
Will Celgene Corporation (NASDAQ:CELG) burn you? Here’s some data to help answer that question. To many traders, hedge funds are perceived as overrated...
Keep Reading →
August 22 - News - Comments
At some point, a company reaches a level of maximum valuation. It doesn’t mean the company becomes bad, but rather all upside is priced in and future...
Keep Reading →
August 22 - News - Comments
Biotech’s the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling...
Keep Reading →
August 19 - News - Comments
When a company is acquired, the acquirer pays a large premium to where the acquired company’s stock price had previously been trading. Because of this...
Keep Reading →
August 13 - News - Comments
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), already quite expensive, spiked higher since takeover rumors surfaced in early July. But can a deal give...
Keep Reading →
August 6 - News - Comments
In 2013, a number of new drugs got approvals from the FDA. This provided a boost to the biotech industry as a whole. Now, this speculative growth market...
Keep Reading →
August 5 - News - Comments
In the last couple of months, we saw two big offers being made – and rejected – in the biotech sector. Both times, the companies that rejected...
Keep Reading →
August 5 - News - Comments
With the SPDR S&P Biotech Index up 43% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the...
Keep Reading →
August 5 - News - Comments
There are few times when your doctor or physician will utter the phrase, “I don’t know” to a patient, but when you’re dealing...
Keep Reading →
August 5 - News - Comments
Three of the biggest names in biotechnology have reported earnings, and their quarters involved very important drug-related information for investors....
Keep Reading →
July 29 - News - Comments
The biotech industry is known for fast paced acquisitions and rapid market consolidation. Larger pharmaceutical companies headed towards patent cliffs...
Keep Reading →
July 29 - News - Comments
You may or may not have heard, but it’s earnings season again. Contrary to popular belief, earnings season does actually take a break for a few...
Keep Reading →
July 22 - News - Comments
In most cases, a biopharmaceutical company chooses to develop either high-priced orphan-designated drugs, or therapeutics to treat large patient populations...
Keep Reading →
July 19 - News - Comments
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. Without my watchlist, I’d be unable to keep up on...
Keep Reading →
July 18 - News - Comments
Buyout! The word gets biotech investors’ blood flowing and their hearts racing. Mere rumors that a biotech stock could get bought out can send shares...
Keep Reading →
July 17 - News - Comments
Questcor Pharmaceuticals Inc (NASDAQ:QCOR) has a particularly fascinating history, having been at the center of controversy for the better part of its...
Keep Reading →
July 17 - News - Comments
Celldex Therapeutics, Inc. (NASDAQ:CLDX), the first antibody-based immunotherapy company, has been a strong buy recommended by several analysts for some...
Keep Reading →
July 17 - News - Comments
According to a Bloomberg report, Roche is prepared to offer $130 a share to purchase Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). In other words, Roche...
Keep Reading →
July 15 - News - Comments
Biotech’s the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling...
Keep Reading →
July 15 - News - Comments
With the SPDR S&P Biotech Index up 33% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the...
Keep Reading →
July 15 - News - Comments
Imagine finding out that you have a disease that only a handful of people around the world have. Kirstie and Catherine Fields don’t have to imagine...
Keep Reading →
July 5 - News - Comments
Love it or hate it, the Patient Protection and Affordable Care Act — commonly referred to as Obamacare — changes the health care landscape...
Keep Reading →
July 5 - News - Comments
The prescription-drug market currently generates a whopping $950 billion in annual sales, and that figure is likely to grow to $1.2 trillion by 2016....
Keep Reading →
July 3 - News - Comments
